Tau and Amyloid PET imaging in normal aging, early Alzheimer's disease and related syndroms.

Cliniques Universitaires Saint-Luc0 sites500 target enrollmentMarch 28, 2019

Overview

Phase: Phase 1
Intervention: Not specified
Conditions: Not specified
Sponsor: Cliniques Universitaires Saint-Luc
Enrollment: 500
Status: Active, not recruiting
Last Updated: last year

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

No summary available.

Registry

who.int

Start Date

March 28, 2019

End Date

TBD

Last Updated

last year

Study Type

Interventional clinical trial of medicinal product

Sex

All

Investigators

Sponsor

Cliniques Universitaires Saint-Luc

Eligibility Criteria

Inclusion Criteria

•Patients with MCI due to AD or mild AD :
•Age at least 45 years
•Able to read and write in French, with a minimum 5 years of formal education
•Attended the Memory Clinic of Cliniques Universitaires Saint\-Luc
•Are able to consent and willing to participate in the study
•Are diagnosed either with mild cognitive impairment (MMSE \= 24/30\) using the Petersen criteria (2004\) or with mild AD dementia (MMSE \= 20/30\) using the McKhann criteria (2011\) by a clinical neurologist.
•Have a study partner or can identify someone willing in principle to be a study partner
•Have either a positive amyloid\-PET scan OR an abnormal measure of Aß\-42 in the CSF OR an abnormal ratio between total tau and Aß\-42 in the CSF.
•Patients with non\-AD syndrome
•Age at least 20 years

Exclusion Criteria

•Presence of any neurological, psychiatric or medical conditions associated with a long\-term risk of significant cognitive impairment or dementia including but not limited to pre\-manifest Huntington’s disease, multiple sclerosis, active alcohol/drug abuse or major psychiatric disorders including current major depressive disorder, schizophrenia, schizoaffective or bipolar disorder.
•Any cancer or history of cancer in the preceding 2 years (excluding cutaneous basal or squamous cell cancer resolved by excision and localized prostate cancer in male subjects)
•Any current medical conditions that are clinically significant and might make the subject’s participation in an investigational trial unsafe, e.g., uncontrolled or unstable disease of any major organ system; history within the last 3 months of any acute illness of a major organ system requiring emergency care or hospitalization, including re\-vascularization procedures; severe renal or hepatic failure; unstable or poorly controlled diabetes mellitus, hypertension, or heart failure; any clinically relevant abnormalities in blood parameters in routine assessments; severe loss of vision, hearing or communicative ability; or any conditions preventing co\-operation or completion of the required assessments in the trial, as judged by the investigator.
•Any contraindications for MRI or PET scan
•Any evidence of intracranial pathology which, in the opinion of the Investigator, may affect cognition, including but not limited to brain tumors (benign or malignant), aneurysm or arteriovenous malformations, territorial stroke (excluding smaller watershed strokes), recent hemorrhage (parenchymal or subdural), or obstructive hydrocephalus. Participants with a MRI scan demonstrating markers of small vessel disease (e.g. white matter changes or lacunar infarcts) judged to be clinically insignificant, or microbleeds are allowed.
•Participation in a clinical trial of an investigational product (IMP) in the 30 days preceding the screening visit. Entering a clinical trial of an investigational product (IMP) is allowed during the current study once the baseline examinations have been performed. The follow\-up examinations scheduled in the current study will be proposed to the participants who will have entered a clinical trial during their participation in the current study, depending on the examinations that are scheduled in the clinical trial.
•Women of child\-bearing potential (WOCBP , non\-menopausal), younger than 55 years old, following any method of contraception not recommended by the Clinical Trial Facilitation Group (CTFG ). The use of a highly effective contraception measure2 should indeed be maintained during any F18 radio\-labelled pharmaceutical exposure, until complete F18 decay (meaning at least a minimum period of 18\-24 hours after injection).
•Pregnancy, or breastfeeding